OP33 Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC): Results from the UPA Phase 3 programme

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalJournal of Crohn's and Colitis
DOIs
Publication statusPublished - 2022

Keywords

  • Medicine
  • Episcleritis
  • Internal medicine
  • Placebo
  • Gastroenterology
  • Arthropathy
  • Ulcerative colitis
  • Primary sclerosing cholangitis
  • Mucocutaneous zone
  • Arthritis
  • Surgery
  • Uveitis
  • Immunology
  • Disease
  • Scleritis
  • Osteoarthritis
  • Pathology
  • Alternative medicine

Cite this